2017
DOI: 10.1111/hepr.12887
|View full text |Cite
|
Sign up to set email alerts
|

Ezetimibe for the treatment of non‐alcoholic fatty liver disease: A meta‐analysis

Abstract: Although ezetimibe attenuated serum liver enzymes and hepatic steatosis and ballooning in six studies, it improved only hepatocyte ballooning in randomized controlled trials. Larger studies and more randomized placebo-controlled trials are necessary to determine the effects of ezetimibe on NAFLD and NASH.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
40
0
3

Year Published

2017
2017
2024
2024

Publication Types

Select...
7
1
1

Relationship

1
8

Authors

Journals

citations
Cited by 67 publications
(43 citation statements)
references
References 34 publications
0
40
0
3
Order By: Relevance
“…Consistent with these reports, the activation of TFEB by ezetimibe, an inhibitor of NPC1L1-dependent cholesterol transport, also protects against steatosis and hepatocyte injury [93]. Interestingly, some of these autophagy inducing drugs are already FDA-approved, and ezetimibe has been evaluated in clinical trials for patients with NASH [94], although conclusive results require larger studies.…”
Section: Implication Of Pparα-lysosomal Crosstalk In Nafldmentioning
confidence: 67%
“…Consistent with these reports, the activation of TFEB by ezetimibe, an inhibitor of NPC1L1-dependent cholesterol transport, also protects against steatosis and hepatocyte injury [93]. Interestingly, some of these autophagy inducing drugs are already FDA-approved, and ezetimibe has been evaluated in clinical trials for patients with NASH [94], although conclusive results require larger studies.…”
Section: Implication Of Pparα-lysosomal Crosstalk In Nafldmentioning
confidence: 67%
“…Though antidiabetic or antihyperlipidemic agents on the market are expected to also be useful for NASH, there have been insufficient evidences of their efficacy for the treatment of NASH. 5,6 It is estimated that the drug market for NASH will reach $US45 billion 2027 in the USA, Japan, and EU 5 (England, France, Germany, Italy, and Spain). This review provides an overview of NASH agents currently in phase 3 trials under development (Table 1).…”
Section: Introductionmentioning
confidence: 99%
“…The presence and severity of liver fibrosis observed in liver biopsy are relevant long‐term prognostic histologic features in patients with NASH and liver fibrosis . However, no US Food and Drug Administration‐approved therapeutic agent is currently available for NASH . Therefore, developing treatment regimens for patients with NASH and severe fibrosis is crucial …”
Section: Introductionmentioning
confidence: 99%
“…2,3 However, no US Food and Drug Administration-approved therapeutic agent is currently available for NASH. 4 Therefore, developing treatment regimens for patients with NASH and severe fibrosis is crucial. 5 Recently, NASH pathogenesis progression has been identified to involve "multiple parallel hits", including the production of gut-derived endotoxin, which is very closely related to Toll-like receptor 4 (TLR4) signaling in promotion of liver fibrosis promotion.…”
Section: Introductionmentioning
confidence: 99%